Senescent cells are cells that have permanently stopped dividing, often in response to DNA damage or stress. Rather than simply retiring quietly, they remain metabolically active and secrete a cocktail of proinflammatory molecules known as the senescence-associated secretory phenotype, or SASP. While this process plays a role in wound healing and tumor suppression in the short term, the gradual accumulation of senescent cells in tissues drives chronic inflammation and has been implicated in conditions ranging from frailty and diabetes to liver fibrosis and cancer. Eliminating these cells, an approach called senolysis, has therefore become one of the most actively pursued strategies in geroscience.

The problem, according to the research team led by Jianghao Qian and Akiko Takahashi, is that most current senolytic drugs work by targeting antiapoptotic pathways that senescent cells deploy to avoid self-destruction. These drugs, including the best-known combination of dasatinib and quercetin, can be effective but carry dose-dependent toxicity that limits their clinical utility. The Japanese team set out to find a fundamentally different way to kill senescent cells, and their search led them to an unexpected candidate: a forty-year-old immunosuppressant sitting in hospital pharmacies around the world.

Their findings reveal that cyclosporine A kills senescent cells through paraptosis-like cell death, a caspase-independent process that does not rely on the conventional apoptosis machinery targeted by existing senolytics. In paraptosis, cells die through dramatic swelling and vacuolization of the endoplasmic reticulum and mitochondria rather than through the orderly fragmentation characteristic of apoptosis. Using live-cell holotomography imaging, the researchers directly visualized this distinctive death process unfolding in senescent cells treated with the drug.

The mechanism behind this selectivity is elegant in its exploitation of a senescent cell’s own weakness. The team discovered that cyclosporine A activates JNK signaling and elevates production of reactive oxygen species, which in turn triggers the apoptosis signal-regulating kinase 1, or ASK1, and its downstream partner, the p38 mitogen-activated protein kinase pathway. Rather than suppressing inflammation as it does in immune cells, the drug amplifies SASP factor expression in senescent cells, dramatically increasing their secretory output.

This SASP overactivation turns out to be lethal precisely because senescent cells are already operating at the limit of their protein-handling capacity. The researchers showed that senescent cells inherently exhibit chronic adaptive endoplasmic reticulum stress responses and heightened ER functional demands, a direct consequence of their extensive secretory activity. The endoplasmic reticulum is the cellular organelle responsible for folding and processing the vast majority of secreted proteins, and the constant flood of inflammatory SASP factors places an enormous burden on this system. When cyclosporine A further disrupts this fragile ER homeostasis by forcing SASP overexpression, the organelle swells catastrophically, and the cell succumbs to paraptosis-like death.

In other words, the very trait that makes senescent cells harmful to tissue, their relentless secretion of inflammatory mediators, becomes the vulnerability that cyclosporine A exploits. Healthy nonsenescent cells, which do not carry this chronic ER stress burden, tolerate the drug at concentrations that prove lethal to their senescent counterparts, providing a mechanistic basis for the drug’s selectivity.

The therapeutic implications were tested directly in an animal model of obesity-associated liver cancer. Obese mice accumulate senescent hepatic stellate cells in their livers, and these cells promote the development of hepatocellular carcinoma by sustaining the inflammatory microenvironment that feeds tumor growth. When the researchers treated obese mice with cyclosporine A, the drug eliminated the senescent stellate cells from the liver and, remarkably, prevented the development of obesity-associated hepatocellular carcinoma. This finding suggests that senolysis via paraptosis could be deployed not merely to slow aging but to intervene in specific cancers driven by senescent cells in the tumor microenvironment.

The study represents a significant conceptual expansion of the senolytic toolkit. By demonstrating that ER stress-induced paraptosis-like cell death can serve as a viable senolysis strategy, the work establishes an entirely new mechanistic class of senotherapy, one that targets the proteostatic fragility of senescent cells rather than their apoptotic defenses. Because cyclosporine A is already an approved clinical drug with well-characterized pharmacology, the path from bench to bedside could be considerably shorter than for entirely novel compounds, although the researchers caution that dose, duration, and the drug’s immunosuppressive effects will all need careful evaluation in the context of senotherapy.

More broadly, the findings add to a growing recognition that aging cells can be eliminated by exploiting metabolic and stress-response vulnerabilities unique to their state. If ER stress amplification proves safe and effective in humans, the strategy could eventually be applied across a broad spectrum of age-related disorders, from fibrotic liver disease to inflammation-driven tumors, offering a way to turn a decades-old transplant drug into a weapon against the biology of aging itself.

Subject of Research: Senolysis via cyclosporine A-induced endoplasmic reticulum stress and paraptosis-like cell death in senescent cells

Article Title: Cyclosporine A provokes paraptosis-like cell death in senescent cells by triggering endoplasmic reticulum stress

Article References: Qian, J., Zhou, X., Lee, K.-S., Loo, T. M., Tanaka, Y., Sugawara, S., Hanyu, A., Kawasaki, H., Yotsumoto, S., Dodo, K., Shirasaki, Y., Kamatani, T., Tanaka, K., & Takahashi, A. (2026). Cyclosporine A provokes paraptosis-like cell death in senescent cells by triggering endoplasmic reticulum stress. Genome Biology. https://doi.org/10.1186/s13059-026-04273-x

Image Credits: AI Generated

DOI: 10.1186/s13059-026-04273-x

Keywords: cellular senescence, senolysis, cyclosporine A, endoplasmic reticulum stress, paraptosis, SASP, hepatocellular carcinoma, aging, cell death, senolytics, Cyclosporine, provokes

The cells at the heart of the study are senescent cells — cells that have permanently exited the cell cycle yet refuse to die. Senescence is not simply wear and tear; it is an actively programmed state that can be triggered by telomere erosion, DNA damage, oncogene activation, or the genotoxic stress of chemotherapy itself. Many front-line cancer drugs work by inflicting precisely the kind of damage that forces cells into this arrested condition. In the short term, the arrangement serves the body well, acting as a brake that keeps damaged cells from turning cancerous. But senescent cells do not retire quietly. They secrete a dense mixture of inflammatory cytokines, growth factors, and tissue-remodeling enzymes known as the senescence-associated secretory phenotype, or SASP. The pro-inflammatory arm of this program, driven by NF-κB and termed the NF-κB-associated SASP, or NASP, by the study’s authors, is considered its most destructive component. It fuels the chronic, low-grade inflammation that accumulates with age, erodes the function of multiple tissues, and — in a cruel twist — can nurture the survival and regrowth of tumors that survive treatment.

For much of the past decade, the field’s answer to these cells has been to eliminate them outright with drugs called senolytics. That strategy has produced striking results in animal models and early clinical studies, but it carries inherent hazards. Clearing senescent cells can strip tissues of cells that still perform useful structural and repair functions, some senolytic compounds produce significant side effects, and it remains unclear which senescent cells in a given tissue should be removed. A quieter strategy has therefore gained ground: senomorphic drugs, which leave senescent cells in place but turn down their harmful secretions. The persistent difficulty has been finding a molecular switch that is specific to the inflammatory SASP, accessible to existing drugs, and capable of acting in cells whose senescent state is already fully established — since most screens test only whether a compound prevents senescence from arising in the first place. The new study identifies a single, clinically validated target, the CDK4/6 kinase pair, that appears to satisfy all three criteria.

CDK4 and CDK6 are best known as gatekeepers of cell division. Paired with their cyclin partners, they phosphorylate the retinoblastoma protein, releasing cells from the G1 checkpoint and sending them into DNA replication. Abemaciclib, an oral drug approved for the treatment of hormone receptor-positive breast cancer, exploits precisely this role to halt tumor proliferation. The researchers asked a different question: beyond controlling the cell cycle, do these kinases help operate the inflammatory program of senescence itself? To find out, they administered short courses of abemaciclib to senescent cells in culture and to mice carrying pre-existing senescent cells, then measured the activity of NASP genes. Crucially, the cells were already senescent before the drug arrived, meaning the experiments tested whether an established inflammatory state could be reversed — the therapeutically relevant scenario — rather than merely prevented. It could. Short-term CDK4/6 inhibition reliably suppressed the NASP signature in both cultured cells and living animals. The senescent cells remained in place, but their inflammatory output dropped sharply, as though the cell’s inflammatory alarm had been switched off without dismantling the rest of the machinery.

The practical consequences emerged most clearly in mice recovering from chemotherapy. Chemotherapy attacks tumors with DNA-damaging agents, but it also seeds tissues throughout the body with newly created senescent cells, and the SASP these cells secrete has a documented darker side: it can promote the proliferation, invasion, and survival of tumor cells that slip through treatment. In the study, short-term abemaciclib treatment reduced the pro-tumorigenic activity of chemotherapy-induced senescent cells, weakening their capacity to support residual cancer. Just as importantly, the drug changed how the animals moved. Mice that received brief CDK4/6 inhibition after chemotherapy showed improved physical function compared with untreated animals, indicating that quieting the senescent-cell secretome can translate into tangible gains in strength and mobility rather than changes confined to molecular readouts. For cancer survivors — a population in which chemotherapy-induced senescence has been increasingly implicated in long-term fatigue, weakness, and organ dysfunction — the result suggests a conceivable path toward a brief drug course that cleans up the inflammatory debris a treatment regimen leaves in its wake.

To exclude the possibility that abemaciclib was acting through some unrelated target, the researchers turned off CDK4 and CDK6 genetically instead of pharmacologically. The genetic knockdown reproduced the drug’s effects, dampening the established inflammatory program and confirming that the mechanism runs through CDK4/6 itself. The distinction matters more than it might appear. Repurposed drugs are notorious for off-target activity, and a senomorphic effect that evaporated under genetic scrutiny would have pointed toward some unknown and potentially undruggable pathway. Instead, the phenocopy pins the biology squarely on the kinases, and it carries a practical corollary: any molecule capable of engaging CDK4/6, not just abemaciclib, might in principle deliver a similar anti-inflammatory benefit, giving drug developers more than one route into the same circuit.

The mechanistic heart of the paper lies downstream of the kinases. When the team traced what happened after CDK4/6 inhibition, the first thing that dimmed was retinoic acid signaling — the gene-regulatory system governed by vitamin A derivatives and their nuclear receptors. Retinoic acid enters the cell, binds receptors such as RARα, and the activated complex then controls the expression of large sets of genes; the new data place this pathway upstream of the senescent cell’s inflammatory output. Supporting that positioning, the RARα antagonist agn194310 reproduced the effect of abemaciclib, suppressing NASP expression on its own. Protein-interaction experiments then exposed the physical wiring of the circuit: CDK4 and CDK6 were found to associate with NF-κB, the transcription factor that orchestrates inflammatory gene expression, while CDK4 additionally bound RARα — and abemaciclib disrupted these interactions. The picture that emerges is of CDK4/6 acting not merely as a cell-cycle engine but as a signaling scaffold, a platform on which retinoic acid receptor signaling and NF-κB-driven inflammatory transcription are coordinated within the senescent cell. Break the scaffold with a drug, and the inflammatory program loses its structural support and falls quiet. It is an unorthodox role for kinases famed for pushing cells through division, and it explains how a cancer drug acquires an anti-inflammatory second life.

The axis also proved consequential in ordinary aging, not only in the burst of senescence that follows chemotherapy. In naturally aged mice, both abemaciclib and agn194310 reduced NASP expression systemically, lowering the inflammatory tone that circulates through the aging body rather than acting in a single tissue, and both treatments improved the animals’ physical performance. The convergence is telling. A clinically approved CDK4/6 inhibitor and an experimental retinoic acid receptor antagonist — two chemically unrelated molecules acting at different nodes of the same circuit — produced matching outcomes, and both mirrored the consequences of removing CDK4/6 genetically. That pattern of evidence is hard to explain unless the CDK4/6–RARα–NF-κB axis is a genuine control point for senescence-associated inflammation during physiological aging. Equally notable is the treatment schedule: benefits appeared after short-term dosing, hinting that intermittent senomorphic therapy — brief pulsed courses rather than continuous treatment — might one day deliver the gains of targeting senescent cells while limiting prolonged drug exposure.

The findings arrive as the senescence field moves toward its first serious clinical tests, and they carry obvious translational appeal. Abemaciclib is already manufactured at scale, prescribed to large numbers of patients, and understood at the level of clinical pharmacology; its known risks in oncology, including diarrhea and reduced white blood cell counts, are well documented, even though appropriate doses and schedules for aging-related indications remain unexplored. The demonstration that brief treatment windows sufficed in mice hints at one way around the hazards of chronically suppressing CDK4/6, which would otherwise interfere with cell proliferation in tissues that renew themselves constantly. The RARα arm of the axis offers a second, independent drug target for the same biological goal, broadening the pharmacological options. None of this yet constitutes a therapy for aging. Mice are not people, doses tolerated in cancer care may not suit older adults, and frail patients or cancer survivors could face particular risks from a drug built to stop cells from dividing. Years of clinical testing would separate these results from any approved senomorphic regimen.

Even so, the study reframes a familiar drug target in an unfamiliar light. CDK4 and CDK6 entered medicine as accelerators of cell division that tumors learn to hijack; they now appear to double as structural supports for the inflammatory machinery of the senescent cell. If that second role holds true in humans, a molecule already validated in hundreds of thousands of patients could eventually be redeployed, at carefully chosen doses and schedules, to defuse the chronic inflammation that shadows both chemotherapy recovery and growing older. The senescent cells themselves would remain in place. Deprived of their inflammatory voice through the CDK4/6–RARα–NF-κB axis, they might finally become the quiet, harmless neighbors that aging biology always intended them to be.

The work focuses on neutrophils, short-lived first responders best known for rapid, destructive pathogen-killing. After spending about a day in circulation, most neutrophils are normally cleared by macrophages in organs such as the liver, spleen, and bone marrow. With advancing age, however, many neutrophils enter senescence instead of being efficiently removed, transitioning into a harmful state that promotes inflammation and tissue dysfunction.

Central to the mechanism is a pro-inflammatory prostaglandin signaling pathway. As mice age, production of prostaglandin E2 (PGE2) rises, and macrophages become enriched with the PGE2 receptor EP2. The study demonstrates that sustained EP2 signaling reduces macrophages’ ability to engulf and digest senescent neutrophils, creating a feedback loop in which immune debris fuels chronic inflammation throughout the body.

To test causality, the team engineered mice in which EP2 could be deleted selectively in tissue-resident macrophages at a chosen time point. When EP2 was absent from these macrophages, aged mice maintained more youthful neutrophil clearance, with fewer senescent neutrophils accumulating in multiple organs. This preservation correlated with improved physiological outcomes spanning brain, heart and skeletal muscle, liver, kidney, and gut-related tissues.

The protective effects were not limited to peripheral tissues. Cognitive decline also slowed in EP2-deleted animals, including performance in memory- and navigation-like behavioral tasks. Inflammatory signatures in relevant tissues and circulating protein profiles shifted toward youthful patterns, particularly in liver-related pathways, aligning with the liver’s role in systemic metabolic regulation.

Beyond genetic deletion, the researchers evaluated an experimental EP2-inhibiting drug. Administering the compound to older mice for two months reduced both total and senescent neutrophil counts toward youthful levels. In cell-based assays, macrophages from treated mice regained robust capacity to clear damaged neutrophils that otherwise accumulated with age.

The team further connected the findings to human biology by leveraging a large dataset of cell-state changes across young, old, and diseased livers. Human samples showed the same broad pattern: increased neutrophil senescence, macrophage decline, and heightened EP2-related activity with age and disease, supporting the translational relevance of the mechanism.

Overall, the study reframes aging-associated organ decline as partly driven by immune cell interaction failure—specifically, macrophage impairment in clearing senescent neutrophils. By blocking a single receptor on tissue-resident macrophages, researchers preserved youthfulness across multiple organs in mice, suggesting a potential pharmaceutical strategy to extend health span.

Subject of Research: Animals
Article Title: Restored clearance of senescent neutrophils by tissue-resident macrophages limits organ aging
News Publication Date: 16-Jul-2026
Web References: http://dx.doi.org/10.1126/science.aea3075
References: 10.1126/science.aea3075
Image Credits: Not provided
Keywords: aging, immune system, tissue-resident macrophages, neutrophil senescence, PGE2, EP2, chronic inflammation, health span

The study’s core focus was on how HHT impacts senescent cells, which accumulate with age and play a pivotal role in driving chronic inflammation and tissue degeneration. Senescent cells are known to secrete pro-inflammatory factors, collectively termed the senescence-associated secretory phenotype (SASP), which exacerbate metabolic anomalies and tissue dysfunction. The authors employed meticulous in vitro and in vivo experiments to validate the hypothesis that HHT serves as a senolytic compound, selectively eliminating these deleterious senescent cells, thereby restoring metabolic homeostasis.

Initial analyses revealed that HHT administration in aged and high-fat diet (HFD)-induced obese mice resulted in pronounced reductions in steady-state markers of senescence across multiple tissues, including adipose tissue, liver, and skeletal muscle. These findings were supported by decreases in p16^Ink4a and p21^Cip1 expression, canonical markers of cellular senescence. More importantly, the treatment led to significant improvements in glucose tolerance and insulin sensitivity, suggesting a direct linkage between senescent cell clearance and enhanced metabolic function.

The researchers provided compelling mechanistic insights into how HHT exerts its senolytic activity. It was found that HHT preferentially induces apoptosis in senescent cells by disrupting their anti-apoptotic pathways. Specifically, HHT downregulated the expression of Bcl-2 family proteins, known to confer survival advantages to senescent cells, thereby sensitizing them to programmed cell death. This selective targeting spares healthy, non-senescent cells, which is a critical advantage over conventional therapies that lack specificity.

A particularly remarkable aspect of the study was the demonstration that HHT treatment extended lifespan in murine models. Longitudinal survival analyses revealed that aged mice receiving HHT exhibited statistically significant lifespan extension compared to vehicle-treated controls. This observation underscores the potential translational value of HHT as a therapeutic agent that not only alleviates metabolic pathology but also promotes healthy aging.

The study’s comprehensive metabolomic profiling further elucidated the beneficial systemic effects of HHT. Treated animals showed reduced systemic inflammation markers and improved liver lipid profiles, highlighting a broad-spectrum amelioration of age-associated metabolic dysregulation. Notably, the attenuated chronic inflammation observed aligns with the suppression of SASP factors, reinforcing the link between senescent cell clearance and systemic rejuvenation.

Importantly, the dosing regimen and safety profile of HHT were carefully characterized. Chronic administration was well-tolerated without observable toxicity or deleterious off-target effects, addressing a common limitation seen with many senolytic compounds. This safety margin enhances the clinical feasibility of repurposing HHT, a drug already approved for certain hematological malignancies, for treating metabolic and aging-related disorders.

The implications of these findings reverberate beyond the realm of metabolic diseases, given that cellular senescence is implicated in a host of chronic conditions such as osteoarthritis, atherosclerosis, and neurodegeneration. By establishing HHT as a potent and selective senolytic agent, the study paves the way for future investigations into its therapeutic potential across diverse age-related pathologies, positioning it as a promising candidate in the emerging field of senotherapeutics.

Another innovative feature of this research lies in its methodological approach, combining transgenic mouse models with sophisticated cellular assays to dissect senescence dynamics. The deployment of senescence reporter mice allowed real-time monitoring of senescent cell burden, enhancing the precision of HHT’s efficacy assessments. Additionally, single-cell RNA sequencing provided unprecedented resolution into the transcriptional reprogramming induced by HHT in different tissues, verifying its targeted action at a molecular level.

From a translational perspective, the utility of HHT could be profound, considering the growing global burden of obesity and type 2 diabetes, both of which are exacerbated by increasing longevity. Current treatments primarily address symptomatic aspects without reversing underlying cellular dysfunction. The senolytic strategy demonstrated here represents a paradigm shift, aiming to eradicate the root cause—the accumulation of senescent cells—that drives metabolic decline with aging.

This work also sparks an important discussion on the potential use of existing drugs with known safety profiles for rejuvenation medicine. Repurposing HHT offers an accelerated path to clinical application, circumventing the lengthy drug development pipeline. Nonetheless, the authors caution that extensive clinical trials will be required to establish optimal dosing, efficacy, and safety in humans, especially considering the complexity of senescence biology and its context-dependent roles.

Moreover, future research is anticipated to explore combination therapies, where HHT might synergize with other interventions such as caloric restriction mimetics or anti-inflammatory agents, enhancing the overall therapeutic outcome. Furthermore, exploring HHT’s effects on human cellular senescence and metabolic disease models will be crucial to validate these promising preclinical findings.

Beyond its immediate clinical implications, this study contributes fundamentally to our understanding of senescence as a modifiable driver of aging and disease. It substantiates the senolytic approach not merely as a theoretical concept, but as a practical, actionable strategy that can be harnessed to improve healthspan and lifespan. Such insights invigorate the field of geroscience, highlighting the therapeutic value of targeting cellular senescence.

In conclusion, the discovery of homoharringtonine’s senotherapeutic capabilities offers an exciting breakthrough in combating age-related metabolic dysfunction and promoting longevity. By eradicating senescent cells that fuel chronic inflammation and insulin resistance, HHT restores metabolic balance, reverses obesity-linked complications, and extends lifespan in preclinical models. As the quest to develop effective anti-aging therapies intensifies, HHT stands out as a potent candidate warranting further investigation, heralding a new era in the treatment of age-associated diseases.

Subject of Research:
Article Title:
Article References:
Kim, EC., Jung, HB., Park, Yk. et al. Homoharringtonine exhibits senotherapeutic activity that mitigates diet- and age-associated obesity and insulin resistance and extends lifespan in mice. Nat Commun 17, 2700 (2026). https://doi.org/10.1038/s41467-026-70475-3
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41467-026-70475-3
Keywords: senotherapeutics, homoharringtonine, cellular senescence, obesity, insulin resistance, aging, lifespan extension, metabolic disorders, Bcl-2, SASP, chronic inflammation, geroscience